10-Q Filing

CARGO THERAPEUTICS, INC. CIK: 1966494 Q3 2023

Filing Information

Form Type	10-Q
Accession Number	`0000950170-23-070075`
Period End Date	20230930
Filing Date	20231213
Fiscal Year	2023
Fiscal Period	Q3
XBRL Instance	crgx-20230930_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 79 Income Statement 53 Cash Flow Statement 77 Stockholders Equity 47

Balance Sheet 79 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$60.34M	USD	Point-in-time
Redeemable convertible preferred stock, par value	`TemporaryEquityParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.87M	USD	Point-in-time
Redeemable convertible preferred stock, shares authorized	`TemporaryEquitySharesAuthorized`	255.58M	shares	Point-in-time
Redeemable convertible preferred stock, shares authorized	`TemporaryEquitySharesAuthorized`	0.00	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$3.07M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$2.06M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$63.42M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$3.93M	USD	Point-in-time
Redeemable convertible preferred stock, shares issued	`TemporaryEquitySharesIssued`	12.50M	shares	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$2.83M	USD	Point-in-time
Redeemable convertible preferred stock, shares outstanding	`TemporaryEquitySharesOutstanding`	0.00	shares	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$2.17M	USD	Point-in-time
Redeemable convertible preferred stock, shares outstanding	`TemporaryEquitySharesOutstanding`	12.50M	shares	Point-in-time
Redeemable convertible preferred stock, aggregate liquidation preference	`TemporaryEquityLiquidationPreference`	$158.59M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$3.37M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$9.15M	USD	Point-in-time
Convertible preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$7.02M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$783.00K	USD	Point-in-time
Total assets	`Assets`	$10.24M	USD	Point-in-time
Convertible preferred stock, shares authorized	`PreferredStockSharesAuthorized`	11.00M	shares	Point-in-time
Total assets	`Assets`	$82.41M	USD	Point-in-time
Convertible preferred stock, shares authorized	`PreferredStockSharesAuthorized`	11.00M	shares	Point-in-time
Convertible preferred stock, shares issued	`PreferredStockSharesIssued`	810,700.00	shares	Point-in-time
Convertible preferred stock, shares issued	`PreferredStockSharesIssued`	810,700.00	shares	Point-in-time
Convertible preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	810,700.00	shares	Point-in-time
Convertible preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	810,700.00	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$3.48M	USD	Point-in-time
Convertible preferred stock, aggregate liquidation preference	`PreferredStockLiquidationPreferenceValue`	$11.00M	USD	Point-in-time
Convertible preferred stock, aggregate liquidation preference	`PreferredStockLiquidationPreferenceValue`	$11.00M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$7.43M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$6.77M	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$1.65M	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$6.78M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	29.00M	shares	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$3.39M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	320.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	320.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	1.09M	shares	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$2.59M	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$1.01M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	1.09M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	1.09M	shares	Point-in-time
Redeemable convertible preferred stock tranche liability	`RedeemableConvertiblePreferredStockTrancheLiability`	$17.57M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	1.09M	shares	Point-in-time
Convertible notes-related party	`ConvertibleNotesPayableToRelatedPartyCurrent`	$11.63M	USD	Point-in-time
Convertible notes	`ConvertibleNotesPayableCurrent`	$9.62M	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$12.71M	USD	Point-in-time
Financial commitment liabilities-related party	`FinancialCommitmentLiabilitiesToRelatedPartyCurrent`	$412.00K	USD	Point-in-time
Financial commitment liabilities	`FinancialCommitmentLiabilitiesCurrent`	$240.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$44.14M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$41.13M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$300.00K	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$1.09M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$250.00K	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$225.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$45.48M	USD	Point-in-time
Total liabilities	`Liabilities`	$41.66M	USD	Point-in-time
Redeemable convertible preferred stock, $0.001 par value; 255,584,255 shares authorized and 12,495,411 shares issued and outstanding at September 30, 2023, respectively, (aggregate liquidation preference of $158,588 at September 30, 2023)	`TemporaryEquityCarryingAmountAttributableToParent`	$150.09M	USD	Point-in-time
Convertible preferred stock, $0.001 par value; 11,000,000 shares authorized and 810,700 issued and outstanding at December 31, 2022 (aggregate liquidation preference of $11,000 at December 31, 2022)	`PreferredStockValue`	$1.00K	USD	Point-in-time
Common stock, $0.001 par value; 320,000,000 and 29,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively; 1,086,262 and 1,091,800 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	`CommonStockValue`	$1.00K	USD	Point-in-time
Common stock, $0.001 par value; 320,000,000 and 29,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively; 1,086,262 and 1,091,800 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	`CommonStockValue`	$1.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.73M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$11.76M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-47.00M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-113.07M	USD	Point-in-time
Total stockholders' deficit	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Total stockholders' deficit	`StockholdersEquity`	$-57.73M	USD	Point-in-time
Total stockholders' deficit	`StockholdersEquity`	$-21.53M	USD	Point-in-time
Total stockholders' deficit	`StockholdersEquity`	$-9.35M	USD	Point-in-time
Total stockholders' deficit	`StockholdersEquity`	$-175.00K	USD	Point-in-time
Total stockholders' deficit	`StockholdersEquity`	$-74.98M	USD	Point-in-time
Total stockholders' deficit	`StockholdersEquity`	$-109.33M	USD	Point-in-time
Total stockholders' deficit	`StockholdersEquity`	$570.00K	USD	Point-in-time
Total liabilities, redeemable convertible preferred stock and stockholders' deficit	`LiabilitiesAndStockholdersEquity`	$10.24M	USD	Point-in-time
Total liabilities, redeemable convertible preferred stock and stockholders' deficit	`LiabilitiesAndStockholdersEquity`	$82.41M	USD	Point-in-time

Income Statement 53 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$20.14M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$22.23M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$48.72M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$8.47M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.58M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.62M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$13.03M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$6.48M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$28.71M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$10.05M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$23.77M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$61.75M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-61.75M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-28.71M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-10.05M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-23.77M	USD	3 Qtrs
Interest expense	`InterestExpense`	$1.60M	USD	3 Qtrs
Interest expense	`InterestExpense`	$2.23M	USD	3 Qtrs
Interest expense	`InterestExpense`	$1.46M	USD	1 Quarter
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$8.34M	USD	3 Qtrs
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$7.65M	USD	1 Quarter
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$-1.19M	USD	3 Qtrs
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$-779.00K	USD	1 Quarter
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$6.45M	USD	3 Qtrs
Loss on extinguishment of convertible notes	`GainsLossesOnExtinguishmentOfDebt`	$-2.32M	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$1.49M	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$1.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-16.00K	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$891.00K	USD	1 Quarter
Net loss and comprehensive loss	`NetIncomeLoss`	$-4.75M	USD	1 Quarter
Net loss and comprehensive loss	`NetIncomeLoss`	$-27.20M	USD	3 Qtrs
Net loss and comprehensive loss	`NetIncomeLoss`	$-35.47M	USD	1 Quarter
Net loss and comprehensive loss	`NetIncomeLoss`	$-66.07M	USD	3 Qtrs
Net loss and comprehensive loss	`NetIncomeLoss`	$-17.88M	USD	1 Quarter
Net loss and comprehensive loss	`NetIncomeLoss`	$-12.29M	USD	1 Quarter
Net loss and comprehensive loss	`NetIncomeLoss`	$-12.71M	USD	1 Quarter
Net loss and comprehensive loss	`NetIncomeLoss`	$-10.16M	USD	1 Quarter
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-79.16	USD	3 Qtrs
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-28.38	USD	1 Quarter
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-47.37	USD	1 Quarter
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-98.15	USD	3 Qtrs
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-79.16	USD	3 Qtrs
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-98.15	USD	3 Qtrs
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-47.37	USD	1 Quarter
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-28.38	USD	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	748,862.00	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	673,175.00	shares	3 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	432,835.00	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	343,635.00	shares	3 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	432,835.00	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	343,635.00	shares	3 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	673,175.00	shares	3 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	748,862.00	shares	1 Quarter

Cash Flow Statement 77 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-4.75M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-27.20M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-35.47M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-66.07M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-17.88M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.29M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.71M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-10.16M	USD	1 Quarter
Loss on extinguishment of convertible notes	`GainsLossesOnExtinguishmentOfDebt`	$-2.32M	USD	3 Qtrs
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$1.63M	USD	3 Qtrs
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$780.00K	USD	3 Qtrs
Noncash interest expense	`PaidInKindInterest`	$1.60M	USD	3 Qtrs
Noncash interest expense	`PaidInKindInterest`	$2.23M	USD	3 Qtrs
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$8.34M	USD	3 Qtrs
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$7.65M	USD	1 Quarter
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$1.00M	USD	3 Qtrs
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$1.23M	USD	3 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$1.71M	USD	3 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$265.00K	USD	3 Qtrs
Depreciation	`Depreciation`	$960.00K	USD	3 Qtrs
Depreciation	`Depreciation`	$500.00K	USD	1 Quarter
Depreciation	`Depreciation`	$234.00K	USD	3 Qtrs
Depreciation	`Depreciation`	$100.00K	USD	1 Quarter
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$-1.19M	USD	3 Qtrs
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$-779.00K	USD	1 Quarter
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$6.45M	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.02M	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$2.75M	USD	3 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$3.55M	USD	3 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$455.00K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$5.78M	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$3.30M	USD	3 Qtrs
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$5.12M	USD	3 Qtrs
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$1.00M	USD	3 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$203.00K	USD	3 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$1.01M	USD	3 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-1.50M	USD	3 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-814.00K	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-17.72M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-52.18M	USD	3 Qtrs
Purchase of property and equipment	`PaymentsToAcquireProductiveAssets`	$5.66M	USD	3 Qtrs
Purchase of property and equipment	`PaymentsToAcquireProductiveAssets`	$1.74M	USD	3 Qtrs
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$520.00K	USD	3 Qtrs
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$358.00K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.26M	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-6.02M	USD	3 Qtrs
Proceeds from issuance of convertible notes, net of issuance costs - related party	`ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCostsFromRelatedParty`	$8.46M	USD	3 Qtrs
Proceeds from issuance of convertible notes, net of issuance costs - related party	`ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCostsFromRelatedParty`	$2.21M	USD	3 Qtrs
Proceeds from issuance of convertible notes, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$7.50M	USD	3 Qtrs
Proceeds from issuance of convertible notes, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$1.29M	USD	3 Qtrs
Proceeds from issuance of convertible preferred stock and tranche commitment, net of issuance costs	`ProceedsFromIssuanceOfConvertiblePreferredStockAndTrancheCommitmentNetOfIssuanceCosts`	$5.50M	USD	3 Qtrs
Proceeds from issuance of redeemable convertible preferred stock and tranche obligations, net of issuance costs	`ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndTrancheObligationsNetOfIssuanceCosts`	$113.91M	USD	3 Qtrs
Proceeds from issuance of restricted stock awards	`ProceedsFromIssuanceOfRestrictedStockAwards`	$3.00K	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$8.00K	USD	3 Qtrs
Payment of deferred initial public offering costs	`PaymentsOfStockIssuanceCosts`	$743.00K	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$116.67M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$21.46M	USD	3 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$58.47M	USD	3 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.49M	USD	3 Qtrs
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$60.34M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$41.00K	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.53M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$60.34M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$41.00K	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.53M	USD	Point-in-time
Reclassification of tranche obligation asset to Series A-1 redeemable convertible preferred stock	`ReclassificationOfTrancheObligationAssetToSeriesA1RedeemableConvertiblePreferredStock`	$1.91M	USD	3 Qtrs
Conversion of convertible notes to shares of Series A-2 redeemable convertible preferred stock	`ConversionOfConvertibleNotesToSharesOfSeriesA2RedeemableConvertiblePreferredStock`	$35.58M	USD	3 Qtrs
Reclassification of shares of Series Seed redeemable convertible preferred stock to mezzanine equity	`ReclassificationOfSharesOfSeriesSeedRedeemableConvertiblePreferredStockToMezzanineEquity`	$9.83M	USD	3 Qtrs
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$1.29M	USD	3 Qtrs
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$1.74M	USD	3 Qtrs
In-process research and development costs in accounts payable, accrued expenses and other current liabilities, and other non-current liabilities	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities`	$412.00K	USD	3 Qtrs
In-process research and development costs in accounts payable, accrued expenses and other current liabilities, and other non-current liabilities	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities`	$1.25M	USD	3 Qtrs
Issuance of shares in exchange for in-process research and development	`StockIssued1`	$72.00K	USD	3 Qtrs
Deferred offering costs related to initial public offering included in accounts payable and accrued expenses and other current liabilities	`DeferredOfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities`	$1.95M	USD	3 Qtrs
Deferred issuance costs for second tranche of Series A-1 redeemable convertible preferred stock in accounts payable and accrued expenses and other current liabilities	`DeferredIssuanceCostsForSecondTrancheOfSeriesA1RedeemableConvertiblePreferredStockInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities`	$19.00K	USD	3 Qtrs

Stockholders Equity 47 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, shares	`TemporaryEquitySharesOutstanding`	0.00	shares	Point-in-time
Beginning balance, shares	`TemporaryEquitySharesOutstanding`	12.50M	shares	Point-in-time
Beginning balance, amount	`TemporaryEquityCarryingAmountAttributableToParent`	$150.09M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-57.73M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-21.53M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-9.35M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-175.00K	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-74.98M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-109.33M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$570.00K	USD	Point-in-time
Reclassification of series seed redeemable convertible preferred stock, amount	`ReclassificationOfSeriesSeedRedeemableConvertiblePreferredStockValue`	$-9.83M	USD	1 Quarter
Issuance of Series Seed convertible preferred stock, amount	`IssuanceOfSeriesSeedConvertiblePreferredStockValue`	$5.50M	USD	1 Quarter
Issuance of common shares for license, amount	`StockIssuedDuringPeriodValueOfCommonSharesForLicense`	$72.00K	USD	1 Quarter
Issuance of restricted stock awards, amount	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	$2.00K	USD	1 Quarter
Issuance of restricted stock awards, amount	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	$1.00K	USD	1 Quarter
Exercise of stock options, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	7,240.00	shares	3 Qtrs
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.00K	USD	1 Quarter
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$6.00K	USD	1 Quarter
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$18.00K	USD	1 Quarter
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$25.00K	USD	1 Quarter
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$43.00K	USD	1 Quarter
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$10.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$592.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.08M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$24.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$31.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$241.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-4.75M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-27.20M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-35.47M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-66.07M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-17.88M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.29M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.71M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-10.16M	USD	1 Quarter
Ending balance, shares	`TemporaryEquitySharesOutstanding`	0.00	shares	Point-in-time
Ending balance, shares	`TemporaryEquitySharesOutstanding`	12.50M	shares	Point-in-time
Ending balance, amount	`TemporaryEquityCarryingAmountAttributableToParent`	$150.09M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-57.73M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-21.53M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-9.35M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-175.00K	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-74.98M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-109.33M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$570.00K	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.